Cereno Scientific releases BioStock article highlighting Q3 Report 2024
Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced the publication of an article by BioStock highlighting the Company’s recently published Q3 Report for 2024.Read the full article here . For further information, please contact: Henrik Westdahl, Director IR & Communications Email: henrik.westdahl@cerenoscientific.com Phone: +46 70-817 59 96 Sten R.